Tweet
Sci Rep
. 2023 Jul 28;13(1):12231.
doi: 10.1038/s41598-023-39210-6. Adjuvant effects of combination monophosphoryl lipid A and poly I:C on antigen-specific immune responses and protective efficacy of influenza vaccines
Chau Thuy Tien Le 1 2 , So Yeon Ahn 3 , Thi Len Ho 1 , Jueun Lee 3 , Dong-Ha Lee 3 , Hye Suk Hwang 4 , Sang-Moo Kang 5 , Eun-Ju Ko 6 7
Affiliations
Toll-like receptor (TLR) agonists improve vaccine immunogenicity and efficacy, but they are currently unlicensed as adjuvants in influenza vaccines. This study aimed to investigate whether a combination of monophosphoryl lipid A (MPL, a TLR4 agonist) and polyriboinosinic polyribocytidylic acid (poly I:C, a TLR3 agonist) can enhance the protective efficacy of an inactivated A/Puerto Rico/8/1934 (A/PR8) H1N1 influenza vaccine against homologous influenza infection and minimize illness outcomes. Results showed that combination MPL and poly I:C adjuvanted influenza vaccination increased the production of antigen-specific antibodies, decreased the levels of cytokines and cellular infiltrates at the infection sites, and induced significant memory T and B cell responses in mice. The results of this study suggest that the combination of MPL and poly I:C can be developed into a possible adjuvant for enhancing the efficacy of influenza vaccines.
. 2023 Jul 28;13(1):12231.
doi: 10.1038/s41598-023-39210-6. Adjuvant effects of combination monophosphoryl lipid A and poly I:C on antigen-specific immune responses and protective efficacy of influenza vaccines
Chau Thuy Tien Le 1 2 , So Yeon Ahn 3 , Thi Len Ho 1 , Jueun Lee 3 , Dong-Ha Lee 3 , Hye Suk Hwang 4 , Sang-Moo Kang 5 , Eun-Ju Ko 6 7
Affiliations
- PMID: 37507413
- PMCID: PMC10382554
- DOI: 10.1038/s41598-023-39210-6
Toll-like receptor (TLR) agonists improve vaccine immunogenicity and efficacy, but they are currently unlicensed as adjuvants in influenza vaccines. This study aimed to investigate whether a combination of monophosphoryl lipid A (MPL, a TLR4 agonist) and polyriboinosinic polyribocytidylic acid (poly I:C, a TLR3 agonist) can enhance the protective efficacy of an inactivated A/Puerto Rico/8/1934 (A/PR8) H1N1 influenza vaccine against homologous influenza infection and minimize illness outcomes. Results showed that combination MPL and poly I:C adjuvanted influenza vaccination increased the production of antigen-specific antibodies, decreased the levels of cytokines and cellular infiltrates at the infection sites, and induced significant memory T and B cell responses in mice. The results of this study suggest that the combination of MPL and poly I:C can be developed into a possible adjuvant for enhancing the efficacy of influenza vaccines.